Browse Trials

➤

In response to COVID-19, some breast cancer trials have temporarily stopped enrolling new patients. Use the contact information in our trial listings to call or email the research site for information about a trial's status.

Visit COVID-19 & Cancer Clinical Trials on Metastatic Trial Talk for regularly updated information about clinical trials during the coronavirus pandemic.

Currently viewing trials
(Last updated: July 01, 2022)

and or

Reset

Zip Code:

Narrow my choices:

Radius (miles): All U.S.

All U.S.

Early stage

Advanced

Treatment

Non-treatment

Phase I II III

Display Only New Trials

AKT

ALK

BARD1

BRCA1/2 (tumor)

BRIP1

CD205

CD70

CHEK2 or CHEK1

ESR1

FGFR

HER2/ERBB2

HLA

MET or C-Met

NTRK

PALB2

PIK3CA or PI3K

PTEN

RAD51

RAF (including BRAF)

RAS (KRAS or NRAS)

ROS1

TP53

NEAREST SITE: 2 miles
Zuckerberg San Francisco General Hospital
San Francisco,CA

VISITS: 3 or 5 visits, over 5 years

PHASE: III

NCT ID: NCT03233191

Breast Cancer Screening Based on Individual Risk Factors and Comparing the Effectiveness of 3D to 2D Mammography

Tomosynthesis Mammographic Imaging Screening Trial (TMIST) Scientific Title

Purpose

To study if risk-based screening for breast cancer is as safe and effective as age-based screening and if (3D) mammography is better than (2D) mammography at finding early-stage tumors.

Who is this for?

Women, age 45 to 74, who have never been diagnosed with DCIS or breast cancer. You must not have had a screening mammogram within the last 11 months Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1: Digital mammogram (2D) <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">if you are premenopausal or postmenopausal with 1 risk factor, mammogram, once a year, for five years</li> <li class="seamTextUnorderedListItem">if you are postmenopausal, mammogram, every 2 years, for five years</li> </ul> Group 2: Digital tomosynthesis mammogram (3D) <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">if you are premenopausal or postmenopausal with 1 risk factor, mammogram, once a year, for five years</li> <li class="seamTextUnorderedListItem">if you are postmenopausal, mammogram, every 2 years, for five years</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Most breast cancer screening guidelines are based upon a woman's age--not her individualized risk of developing breast cancer. </li> <li class="seamTextUnorderedListItem">For this trial, you will receive annual mammograms if you are premenopausal or postmenopausal with at least one risk factor.</li> <li class="seamTextUnorderedListItem">Risk factors if you are 45-69: dense breasts, a first degree relative with breast cancer, an inherited genetic mutation that increases your risk of developing cancer, or taking hormone therapy.</li> <li class="seamTextUnorderedListItem">Risk factors if you are 70-74: dense breasts or taking hormone therapy.</li> <li class="seamTextUnorderedListItem">Digital tomosynthesis (3D) mammography is approved by the FDA but is not considered the standard of care for breast cancer screening.</li> <li class="seamTextUnorderedListItem">Digital (2D) mammography is the standard of care for breast cancer screening.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03233191' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://ecog-acrin.org/tmist' target='_blank'>ECOG-ACRIN Cancer Research Group Trial Information Page: TMIST</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.breastcancer.org/symptoms/testing/types/dig_tomosynth' target='_blank'>Breastcancer.org: Digital Tomosynthesis</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.hopkinsmedicine.org/breast_center/treatments_services/breast_cancer_screening/digital_mammography/index.html' target='_blank'>Johns Hopkins Medicine: Digital Mammography</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/news-events/cancer-currents-blog/2017/tmist-breast-cancer-screening' target='_blank'>NCI Cancer Currents Blog: TMIST Trial Aims to Provide Clarity on Breast Cancer Screening Approaches</a> </li></ul>

NEAREST SITE: 3 miles
University of California San Francisco
San Francisco,CA

VISITS: Online surveys

PHASE: NA

NCT ID: NCT02620852

WISDOM Study: Women Informed to Screen Depending on Measures of Risk

Enabling a Paradigm Shift: A Preference-Tolerant RCT of Personalized vs. Annual Screening for Breast Cancer Scientific Title

Purpose

To learn if risk-based breast screening is as safe and effective as annual mammogram screening for reducing risk and detecting breast cancer.

Who is this for?

Women between the ages of 40 and 70 who have never been diagnosed with breast cancer or ductal carcinoma in situ (DCIS). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups, or you can choose your study group. Group 1: Personalized, Risk-Based Screening <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Screening recommendations based on comprehensive, personal risk assessment</li> <li class="seamTextUnorderedListItem">Saliva sample genetic test</li> <li class="seamTextUnorderedListItem">Online, annual health questionnaires</li> </ul> Group 2: Standard Annual Screening <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Screening recommendation for annual mammograms</li> <li class="seamTextUnorderedListItem">Online, annual health questionnaires</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Personalized risk-based screening will take multiple risk factors into consideration, including genetic markers, to determine how often you should have a mammogram.</li> <li class="seamTextUnorderedListItem">This study will help researchers learn if risk-based screening, which helps women learn more about their personal breast cancer risk, is less stressful and as successful at detecting breast cancer as annual screening. </li> <li class="seamTextUnorderedListItem">This study is available in English and Spanish.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02620852' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.thewisdomstudy.org/' target='_blank'>WISDOM: Study Information Page</a> </li></ul>

NEAREST SITE: 28 miles
Stanford University Medical Center
Palo Alto,CA

VISITS: 1 visit that coincides with surgery

PHASE: II

NCT ID: NCT04440982

Detection of Cancer Cells During Lumpectomy in Women Who Received Therapy Before Surgery

Feasibility Study to Evaluate Performance of the LUM Imaging System for Intraoperative Detection of Residual Tumor in Patients With Breast Cancer Receiving Neoadjuvant Therapy Scientific Title

Purpose

To study the safety and effectiveness of using the LUM Imaging System during breast conserving surgery (lumpectomy) to identify any remaining cancer cells in the tissue around where the tumor was removed.

Who is this for?

Women with DCIS or stage I, stage II or stage III breast cancer who will have a lumpectomy (breast conserving surgery) after receiving treatment. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups and receive the following: Group 1: LUM Imaging System to see if cancer cells remain <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LUM015, by IV, 2 to 6 hours prior to surgery</li> <li class="seamTextUnorderedListItem">LUM imaging to decide if more breast tissue should be removed during surgery</li> </ul> Group 2: Standard Care to see if cancer cells remain <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LUM015, by IV, 2 to 6 hours prior to surgery</li> <li class="seamTextUnorderedListItem">Standard care to decide if more breast tissue should be removed during surgery</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The LUM Imaging System uses a dye, called LUM015, that is injected into your body before surgery.</li> <li class="seamTextUnorderedListItem">The LUM015 dye then attaches to cancer cells in breast tissue. This can help the surgeon determine if cancer cells remain in the tumor bed after the DCIS or tumor has been removed. If cancer cells remain, your surgeon will remove more tissue.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04440982' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.komen.org/breast-cancer/treatment/type/surgery/assessing-margins/' target='_blank'>Susan G. Komen: Assessing Margins after Breast Surgery</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.lumicell.com/product-technology/technology-overview.php' target='_blank'>Lumicell Medical Device Information Page: Lumicell System</a> </li></ul>

NEAREST SITE: 40 miles
Providence Queen of The Valley
Napa,CA

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT03723928

Imaging and Tumor Mark Tests to Monitor Metastatic HR Positive, HER2 Negative Breast Cancer

Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored With Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients With Metastatic Hormone Receptor Positive Breast Cancer (SWOG-S1703) Scientific Title

Purpose

To study if blood tests that look for tumor markers are as good as or better than imaging with PET and/or CT scans (the current standard of care) to determine if a tumor is growing.

Who is this for?

People with metastatic (stage IV) hormone positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer who are planning to have first line treatment for metastatic disease or have started treatment within the past month, and have at least one elevated tumor marker. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1: Standard of care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Imaging (CT and/or PET scans), at least every 3 months, ongoing</li> <li class="seamTextUnorderedListItem">Tumor Marker Test, if ordered by your doctor</li> </ul> Group 2: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tumor Marker Tests, every 1 to 2 months, ongoing</li> <li class="seamTextUnorderedListItem">Imaging (CT and/or PET scans), only if need is shown by a Tumor Marker Test</li> </ul> Additional procedures <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood draws</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This imaging trial will compare using blood tests to PET/CT scans for monitoring tumor growth. </li> <li class="seamTextUnorderedListItem">The tumor markers that will be tested for in this study are CA 15-3, CA27.29, and CEA.</li> <li class="seamTextUnorderedListItem">The imaging tests will be those ordered by your doctor.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03723928' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/symptoms/testing/types/blood_marker' target='_blank'>Breastcancer.org: Blood Marker Tests</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.net/about-us/collaborations/top-five-list-oncology/choosing-wisely®-top-five-cancer-related-tests-procedures-and-treatments-many-patients-do-not-need/topic-4-follow-tumor-marker-tests-and-imaging-tests-people-treated-breast-cancer' target='_blank'>ASCO Cancer.net: Follow-up Tumor Marker Tests and Imaging Tests for People Treated for Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/about-cancer/diagnosis-staging/diagnosis/tumor-markers-fact-sheet' target='_blank'>NCI: Tumor Markers</a> </li><li class='seamTextUnorderedListItem'><a href='https://ozarkscancerresearch.org/wp-content/uploads/2019/04/SWOG-S1703.pdf' target='_blank'>Cancer Research for the Ozarks: Trial Information Page</a> </li></ul>

NEAREST SITE: 160 miles
Gene Upshaw Memorial Tahoe Forest Cancer Center
Truckee,CA

VISITS: 2 visits over 4 months

PHASE: II

NCT ID: NCT04316117

Using PET/CT Scans to See How Breast Cancer That Has Spread to the Bones is Responding to Therapy

FDG PET to Assess Therapeutic Response in Patients With Bone-Dominant Metastatic Breast Cancer, FEATURE Scientific Title

Purpose

To study if PET/CT scans with a FDG tracer find tumors missed by standard of care imaging and can see how breast cancer tumors that have spread to the bones are responding to therapy.

Who is this for?

People with stage IV (metastatic) breast cancer that has spread to their bones and who have not received more than 3 chemotherapies for metastatic disease. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">FDG tracer, by IV, followed by PET/CT scan, 2 times (1 scan before treatment, 1 scan 3 months after starting treatment)</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cancer cells.</li> <li class="seamTextUnorderedListItem">This imaging trial will use a tracer called FDG (fluorodeoxyglucose). </li> <li class="seamTextUnorderedListItem">FDG produces color-coded images that show normal and cancerous tissue.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04316117' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://ecog-acrin.org/clinical-trials/ea1183-educational-materials' target='_blank'>ECOG-ACRIN Study Information Page: FEATURE</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancerresearchuk.org/about-cancer/cancer-in-general/tests/pet-ct-scan' target='_blank'>Cancer Research UK: PET-CT Scan</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.docpanel.com/blog/post/understanding-your-fdg-pet-scan' target='_blank'>Docpanel: Understanding Your FDG PET Scan</a> </li></ul>

NEAREST SITE: 336 miles
University of California at Los Angeles
Los Angeles,CA

VISITS: 1 visit

PHASE: NA

NCT ID: NCT04297020

Studying the Effects of Anti-Estrogen Therapy on the Brain of Women with Stage I-III Breast Cancer

Brain Health in Breast Cancer Survivors: Interaction of Menopause and Endocrine Therapy Scientific Title

Purpose

To see if anti-estrogen therapy affects brain health.

Who is this for?

Women between the ages of 35 and 65 who are currently taking anti-estrogen therapy for stage I, stage II, or stage III breast cancer and who did not receive chemotherapy. This trial is also enrolling women who have never been diagnosed with breast cancer. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">1 Brain fMRI (functional MRI)</li> <li class="seamTextUnorderedListItem">Cognitive testing</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This trial will use an advanced brain MRI technique called functional MRI (fMRI).</li> <li class="seamTextUnorderedListItem">fMRI measures changes in blood flow that happen during mental activity. </li> <li class="seamTextUnorderedListItem">Research suggests that the cognitive issues experienced by some women who receive treatment for breast cancer--also called <q>chemo brain</q>--may actually be caused by anti-estrogen therapy and not chemotherapy.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04297020' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.medscape.com/viewarticle/932091' target='_blank'>MedScape: In Breast Cancer, Is Chemobrain Really Endocrine Brain?</a> </li><li class='seamTextUnorderedListItem'><a href='https://en.wikipedia.org/wiki/Functional_magnetic_resonance_imaging' target='_blank'>Wikipedia: Functional MRI</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.radiologyinfo.org/en/info.cfm?pg=fmribrain' target='_blank'>RadiologyInfo.org: fMRI</a> </li></ul>

NEAREST SITE: 348 miles
USC / Norris Comprehensive Cancer Center
Los Angeles,CA

VISITS: 1 visit

PHASE: II

NCT ID: NCT02398773

Predicting Which Tumors in People With Newly Diagnosed Metastatic ER+ Breast Cancer Will Respond to Hormone Therapy

[18F] Fluoroestradiol (FES) PET as a Predictive Measure for Endocrine Therapy in Patients With Newly Diagnosed Metastatic Breast Cancer (EAI142) Scientific Title

Purpose

To see if FES-PET/CT scans can predict how ER+ breast cancer will respond to anti-hormone therapy.

Who is this for?

People with newly diagnosed metastatic (stage IV) breast cancer who have not yet received hormone therapy for metastatic disease and who have at least one tumor that is estrogen receptor positive (ER+). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

All participants will undergo the following up to 30 days before starting standard hormone therapy: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">FES tracer, by IV over 2 minutes</li> <li class="seamTextUnorderedListItem">followed by PET/CT imaging</li> </ul> May undergo a second FES-PET/CT at least 24 hours and no later than 10 days after the initial study
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tracers are chemicals that are used to find cancer cells in the body. </li> <li class="seamTextUnorderedListItem">This imaging trial will use the tracer fluoroestradiol (FES)--a tracer that finds estrogen receptors in breast cancer tumors. </li> <li class="seamTextUnorderedListItem">Giving an FES tracer before a PET/CT scan may help doctors find ER+ breast cancer cells that have spread to other parts of the body (metastasized).</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02398773' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayo.edu/research/clinical-trials/cls-20347030' target='_blank'>Mayo Clinic Trial Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.radiologyinfo.org/en/info.cfm?pg=pet' target='_blank'>RadiologyInfo.org: Positron Emission Tomography - Computed Tomography (PET/CT)</a> </li><li class='seamTextUnorderedListItem'><a href='http://clincancerres.aacrjournals.org/content/23/2/407' target='_blank'>AACR: Estrogen Receptor Binding and Glycolytic Activity Predict Progression-Free Survival on Endocrine Therapy</a> </li></ul>

NEAREST SITE: 374 miles
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange,CA

VISITS: 1 visit a week for 3 months

PHASE: II

NCT ID: NCT02436993

Two Chemotherapies and a Targeted Therapy Before Surgery for Stage I-III Breast Cancer

A Phase II Study of Breast Cancer Treatment Using Weekly Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting Scientific Title

Purpose

To evaluate the safety and effects (good and bad) of giving chemotherapy with Avastin or Perjeta before surgery and to study whether magnetic resonance imaging (MRI) is a good tool for monitoring and predicting how a tumor will respond to the treatment.

Who is this for?

Women with stage I, stage II, or stage III breast cancer who have not yet had surgery or any other treatment. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be assigned to 1 of 2 groups and receive the following for 3 months before surgery: Group 1: HER2-negative <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Carboplatin (Paraplatin®), by IV, weekly</li> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), weekly</li> <li class="seamTextUnorderedListItem">Bevacizumab (Avastin®), every other week</li> </ul> Group 2: HER2-positive <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Carbolplain (Paraplatin®), by IV, weekly</li> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), by IV, weekly</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®), by IV, weekly</li> <li class="seamTextUnorderedListItem">Pertuzumab (Perjeta®), by IV, every 3 weeks</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Carboplatin (Paraplatin®) and paclitaxel (Taxol®) are chemotherapy drugs routinely used to treat breast cancer.</li> <li class="seamTextUnorderedListItem">Bevacizumab (Avastin®) is a targeted therapy that keeps tumors from growing the blood vessels they need to survive.</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®) and pertuzumab (Perjeta®) are targeted therapies used to treat HER2 positive breast cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02436993' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://ww5.komen.org/BreastCancer/Neoadjuvant.html' target='_blank'>Susan G. Komen: Neoadjuvant Therapies</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.breastcancer.org/treatment/targeted_therapies/avastin' target='_blank'>Breastcancer.org: Avastin</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.breastcancer.org/treatment/targeted_therapies/herceptin' target='_blank'>Breastcancer.rog: Herceptin</a> </li></ul>

NEAREST SITE: 602 miles
Huntsman Cancer Institute
Salt Lake City,UT

VISITS: 1 visit

PHASE: II

NCT ID: NCT04252859

Using a PET/CT Scan to Find Lobular Breast Cancer Cells Before Surgery for Stage I-IV Lobular Breast Cancer

[18F]Fluoroestradiol-PET/CT Imaging of Invasive Lobular Carcinoma Scientific Title

Purpose

To study whether a PET/CT scan using a (18F) FES tracer is more effective at finding lobular breast cancer cells than the standard of care.

Who is this for?

People diagnosed with stage I, stage II or stage III lobular breast cancer within the last 3 months and who have not yet had surgery and people with stage IV (metastatic) lobular breast cancer diagnosed within the last 3 months Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PET/CT scan using (18F) FES tracer, 1 time</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer. A tracer looks for and attaches to cancer cells.</li> <li class="seamTextUnorderedListItem">Lobular breast cancer is a subtype of breast cancer. It is estimated that 10 to 15 percent of all breast cancers are lobular. </li> <li class="seamTextUnorderedListItem">Standard of care PET/CT scans that use a FDG tracer generally do not find lobular breast cancer tumors as well as they find ductal breast cancer tumors and PET/CT scans are not usually given to people with stage I-II lobular breast cancer. </li> <li class="seamTextUnorderedListItem">This imaging trial will use a tracer called (18F)Fluoroestradiol (FES). Researchers believe this tracer is better at locating and attaching to lobular cancer cells than the standard of care tracer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04252859' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://lobularbreastcancer.org/imagingilc/' target='_blank'>Lobular Breast Cancer Alliance: Imaging and Lobular Breast Cancer</a> </li></ul>

NEAREST SITE: 602 miles
Huntsman Cancer Institute
Salt Lake City,UT

VISITS: 2 visits over 1 week

PHASE: II

NCT ID: NCT02317783

Using Brain Imaging to Study the Effect of Chemotherapy on the Brain

Amyloid Plaque Deposition in Chemotherapy-Induced Cognitive Impairment Scientific Title

Purpose

To use PET scans to study how chemotherapy affects the brain.

Who is this for?

Women with stage I, stage II, or stage III breast cancer who received chemotherapy after surgery within the last three years. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive 2 FDG-PET scans using flutemetamol over a week
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Many cancer patients have thinking and memory problems due to cancer or its treatments. The reasons for this <q>mental fog,</q> referred to as chemo brain, are not always known.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02317783' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://clinicaltrials.gov/ct2/show/NCT02317783?term=NCT02317783&rank=1' target='_blank'>ClinicalTrials.gov: Trial Information</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.cancer.org/treatment/treatmentsandsideeffects/physicalsideeffects/chemotherapyeffects/chemo-brain' target='_blank'>Cancer.org: Chemo Brain</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm372261.htm' target='_blank'>FDA.gov: Imaging Drug, Flutemetamol</a> </li></ul>

NEAREST SITE: 1509 miles
UT Southwestern Medical Center
Dallas,TX

VISITS: 1-2 visits

PHASE: NA

NCT ID: NCT03067467

Metabolic Differences Between Brain Metastases and Normal Brain Tissue

Investigating Metabolic Characteristics of Intracranial Malignancy In Vivo Using Hyperpolarized Carbon-13 Magnetic Resonance Spectroscopic Imaging (MRSI) Scientific Title

Purpose

To look at how the metabolism of brain metastases differs from normal tissue.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastases) and who have not received prior chemotherapy or radiation for these metastases. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will undergo the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Brain MRSI (a type of MRI), with contrast, by IV</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MRSI (Magnetic Resonance Spectroscopic Imaging) is a technique used to visualize tumor metabolism in real-time.</li> <li class="seamTextUnorderedListItem">Learning how the metabolism of brain metastases differs from normal tissue may lead to the development of new targeted therapies.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03067467' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mbcalliance.org/marina-kaplan-project' target='_blank'>The Marina Kaplan Project: Breast Cancer Brain Metastases Initiative</a> </li></ul>

NEAREST SITE: 1643 miles
M D Anderson Cancer Center
Houston,TX

VISITS: 1 visit

PHASE: NA

NCT ID: NCT03685539

DECT Imaging Before Stereotactic Radiosurgery to Detect Brain Metastases

Advanced CT Imaging Optimization for the Detection of Intracranial Metastasis Scientific Title

Purpose

To study how well DECT works for imaging breast cancer that has spread to the brain (brain metastases).

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastases) and who have not received brain radiation. You must be planning to receive treatment with Gamma Knife radiosurgery. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">DECT imaging up to 7 days before Gamma Knife radiosurgery</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Dual-energy computed tomography (DECT) imaging is more specific than computed tomography (CT) imaging.</li> <li class="seamTextUnorderedListItem">DECT may help find and diagnose tumor cells and find out how far the tumor cells have spread in the brain.</li> <li class="seamTextUnorderedListItem">Gamma Knife radiosurgery is a type of stereotactic radiosurgery.</li> <li class="seamTextUnorderedListItem">Stereotactic radiosurgery delivers high-dose, precisely-targeted radiation in fewer doses than traditional radiation therapy.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03685539' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://radiology.ucsf.edu/blog/new-applications-dual-energy-ct-dect' target='_blank'>UCSF Department of Radiology and Biomedical Imaging: Dual-Energy Computed Tomography</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayoclinic.org/tests-procedures/brain-stereotactic-radiosurgery/about/pac-20384679' target='_blank'>Mayo Clinic: Gamma Knife Radiosurgery</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/types/metastatic/brain-metastasis' target='_blank'>Breastcancer.org: Stereotactic Radiosurgery</a> </li></ul>

NEAREST SITE: 1643 miles
M D Anderson Cancer Center
Houston,TX

VISITS: 8 visits over 8 months

PHASE: NA

NCT ID: NCT04870645

Advanced MRI Scan Before and After Radiation Therapy to Detect Brain Metastases

Advanced MRI for Intracranial Metastasis Treated With Stereotactic Radiosurgery Scientific Title

Purpose

To compare a new type of imaging technique with standard MRI to see if it provides better images.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain who are planning to receive radiation therapy for brain mets. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Standard MRI and advanced MRI, over 60 minutes, within 2 weeks before the start of brain radiation</li> <li class="seamTextUnorderedListItem">7 additional MRIs, over 60 minutes each, between 1-4 months apart</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Sequences during magnetic resonance imaging (MRI) is a new, advanced type of imaging technique.</li> <li class="seamTextUnorderedListItem">Researchers believe this technique might provide better images compared to standard MRI imaging.</li> <li class="seamTextUnorderedListItem">Diagnostic procedures, such as MRI, may help find and diagnose cancer and find out how far the disease has spread.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04870645' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 1643 miles
M D Anderson Cancer Center
Houston,TX

VISITS: 1 to 2 visits

PHASE: I

NCT ID: NCT03604315

An Experimental PET/CT Scan to Find PARP-Expressing Tumor Cells

Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CT Scientific Title

Purpose

To study the safety and effectiveness of using a PET/CT scan with the experimental tracer F-18.

Who is this for?

People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer or DCIS. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">F-18 tracer, by IV, then a PET/CT scan</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cancer cells.</li> <li class="seamTextUnorderedListItem">The tracer used in this imaging trial is called fluorine F 18 fluorthanatrace (F-18)--it binds to PARP expressing tumor cells (PARP is a protein over expressed in certain cancers). </li> <li class="seamTextUnorderedListItem">You do not need to have an inherited BRCA1/2 mutation to enroll in this trial but researchers are studying whether F-18 works better in inherited BRCA1/2+ cancers. </li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of solid tumors.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03604315' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://my.clevelandclinic.org/health/diagnostics/10123-pet-scan' target='_blank'>Cleveland Clinic: PET Scan</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/fluorine-f-18-fluorthanatrace' target='_blank'>NCI Drug Dictionary: Fluorine F 18 Fluorthanatrace</a> </li></ul>

NEAREST SITE: 1678 miles
University of Wisconsin Carbone Cancer Center
Madison,WI

VISITS: 1 visit every 3 to 4 weeks, ongoing

PHASE: NA

NCT ID: NCT04174352

Imaging to Personalize Amount of Tamoxifen in Advanced, ER+, HER2- Breast Cancer With a ESR1 Mutation

A Pilot Study of FES Imaging to Optimize Tamoxifen Dose for Metastatic Breast Cancer Patients With ESR1 Mutations Scientific Title

Purpose

To study if FES-PET/CT scans can help find a personalized dose of tamoxifen (Nolvadex®).

Who is this for?

People with advanced (some stage III) or metastatic (stage IV), estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer that tests positive for a ESR1 mutation. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tamoxifen (Nolvadex®), by mouth, daily, ongoing</li> <li class="seamTextUnorderedListItem">FES PET/CT scan, every 3 to 4 weeks, ongoing</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tamoxifen (Nolvadex®) is an anti-estrogen therapy used to treat hormone-sensitive breast cancer.</li> <li class="seamTextUnorderedListItem">ESR1 mutations in breast cancer may affect how well tamoxifen works against tumor cells. </li> <li class="seamTextUnorderedListItem">Tracers are chemicals that are used to find cancer cells in the body during a PET scan. The imaging trial will use the tracer fluoroestradiol (FES)--it finds estrogen receptors in breast tumors. </li> <li class="seamTextUnorderedListItem">The FES tracer may also show how tamoxifen is affecting your tumors. Researchers may use this information to increase your dose of tamoxifen.</li> <li class="seamTextUnorderedListItem">Targets or mutations: ESR1</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04174352' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.net/research-and-advocacy/asco-care-and-treatment-recommendations-patients/hormonal-therapy-metastatic-breast-cancer' target='_blank'>ASCO Cancer.net: Hormonal Therapy for Metastatic Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/hormonal/serms/tamoxifen' target='_blank'>Breastcancer.org: Tamoxifen</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.targetedonc.com/view/more-effective-therapies-needed-for-patients-with-esr1mutated-breast-cancer' target='_blank'>Targeted Oncology: More Effective Therapies Needed For Patients With ESR1-Mutated Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.karger.com/Article/FullText/481428' target='_blank'>Journal Article: Are We Ready to Use ESR1 Mutations in Clinical Practice</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.ijcem.com/files/ijcem0076055.pdf' target='_blank'>Journal Article: The Role of PET Imaging Probes for Early Monitoring the Response to Tamoxifen</a> </li></ul>

NEAREST SITE: 2438 miles
Walter Reed Army Medical Center
Washington,DC

VISITS: 1 visit

PHASE: NA

NCT ID: NCT01322750

A Circulating Tumor Cell Test To Screen For Breast Cancer At Walter Reed National Military Medical Center

Circulating Tumor Cells (CTCs): A Potential Screening Test for Clinically Undetectable Breast Carcinoma Scientific Title

Purpose

To study if a blood test for circulating tumor cells (CTCs) can reliably find breast cancer before your cancer has become clinically detectable (seen on a mammogram, ultrasound, or other imaging).

Who is this for?

People without breast cancer and people with DCIS, stage I, stage II, or stage III breast cancer who are having a diagnostic or therapeutic procedure (biopsy, lumpectomy, mastectomy) done at Walter Reed National Military Medical Center. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will have your blood drawn
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Scientists are researching new techniques to screen for breast cancer.</li> <li class="seamTextUnorderedListItem">Breast cancer cells can leave the tumor and move through the blood stream before the tumor is clinically detectable.</li> <li class="seamTextUnorderedListItem">Circulating tumor cell tests look for these traveling cancer cells and may provide a simple, reliable, and cost-effective form of breast cancer screening.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT01322750' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.cbcp-research.org' target='_blank'>Walter Reed National Military Medical Center: Clinical Breast Care Project</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/screening-testing/blood-chemistry-tests' target='_blank'>Breastcancer.org: Blood Chemistry Tests</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/types/breast/patient/breast-screening-pdq' target='_blank'>NCI: Breast Cancer Screening</a> </li></ul>

NEAREST SITE: 2567 miles
Memorial Sloan Kettering Cancer Center
New York,NY

VISITS: 1-2 visits

PHASE: NA

NCT ID: NCT01916122

A New Approach to Studying How ER+ Tumors Respond to Treatment

Fluorestradiol (FES) PET/CT for Imaging Estrogen Receptor Status Scientific Title

Purpose

To study whether PET/CT scans that use a FES tracer can show if ER+ breast cancer is responding to therapy.

Who is this for?

People with stage I, stage II, stage III, or metastatic (stage IV) estrogen receptor positive (ER+) breast cancer who are receiving treatment at Memorial Sloan Kettering Cancer Center. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">FES tracer, by IV</li> <li class="seamTextUnorderedListItem">followed by PET/CT scan</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cancer cells. </li> <li class="seamTextUnorderedListItem">A tracer called 16a-18F-fluoroestradiol (FES) looks for and attaches to estrogen receptors. </li> <li class="seamTextUnorderedListItem">Researchers are using this imaging trial to study if the tracer FES can be used to monitor the effect a cancer therapy is having on the cancer cells.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT01916122' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://medlineplus.gov/ency/article/003827.htm' target='_blank'>MedlinePlus: PET Scan</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.sciencedaily.com/releases/2018/08/180806104245.htm' target='_blank'>Science Daily: PET Tracer Identifies Estrogen Receptor Expression Differences in Breast Cancer</a> </li></ul>

NEAREST SITE: 2693 miles
Beth Israel Deaconess Medical Center
Boston,MA

VISITS: Number of visits unavailable

PHASE: II

NCT ID: NCT03285412

Additional Therapy after Standard Treatment for Women with Stage I-III, ER+, HER2- Breast Cancer with Residual Disease by ctDNA Testing

Phase II Study of CDK 4/6 Inhibitor, LEE011 (Ribociclib), in Combination With Adjuvant Endocrine Therapy at Varying Duration for ER-positive Breast Cancer (LEADER) Scientific Title

Purpose

To study the anti-cancer activity, safety, and side effects of giving additional treatment with a CDK 4/6 inhibitor to treat residual disease defined as testing positive for ctDNA.

Who is this for?

Women with stage I, stage II, or stage III estrogen receptor-positive (ER+), HER2 negative (HER2-) breast cancer who have completed treatment (other than hormone therapy) for breast cancer and test positive for detectable disease with a ctDNA test. You will be given a blood test to look for ctDNA. You may enroll in this trial up to ten years after diagnosis. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

If your ctDNA test comes back positive for residual disease, you will be randomly assigned to 1 of 2 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Ribociclib (Kisqali®), by mouth, daily (3 weeks on, 1 week off)</li> <li class="seamTextUnorderedListItem">Physician's choice of hormone therapy</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Physician's choice of hormone therapy</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Circulating tumor DNA (ctDNA) are small bits of cancer cell DNA that specific tests can find in the bloodstream.</li> <li class="seamTextUnorderedListItem">Researchers are studying if a test looking for ctDNA in the bloodstream can determine if there will be a recurrence (coming back) of a women's breast cancer.</li> <li class="seamTextUnorderedListItem">The ctDNA blood test used in this trial is called Signatera.</li> <li class="seamTextUnorderedListItem">This trial is also studying if a recurrence can be stopped or delayed by giving women with a positive ctDNA test additional treatment.</li> <li class="seamTextUnorderedListItem">The additional treatment in this trial includes Ribociclib (Kisqali®).</li> <li class="seamTextUnorderedListItem">Palbociclib is commonly used with anti-estrogen therapy for metastatic, hormone-positive (ER+ and/or PR+), HER2-negative (HER2-) breast cancer, but its use in this trial is considered experimental.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03285412' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.natera.com/oncology/signatera-advanced-cancer-detection/' target='_blank'>Natera ctDNA Test Information Page: Signature</a> </li><li class='seamTextUnorderedListItem'><a href='https://medlineplus.gov/genetics/understanding/testing/circulatingtumordna/' target='_blank'>What is Circulating Tumor DNA and How is it Used to Diagnose and Manage Cancer?</a> </li><li class='seamTextUnorderedListItem'><a href='https://ascopost.com/issues/january-25-2021/a-tale-of-two-cdk46-inhibitors-in-early-breast-cancer/' target='_blank'>The ASCO Post: A Tale of Two CDK4/6 Inhibitors in Early Breast Cancer</a> </li></ul>

NEAREST SITE: 2693 miles
Beth Israel Deaconess Medical Center
Boston,MA

VISITS: Number of visits unavailable, over 1 year

PHASE: NA

NCT ID: NCT02666378

Detecting Treatment-Related Cardiotoxicity in HER2 Positive Breast Cancer

Imaging Markers of Subclinical Cardiotoxicity in Breast Cancer Scientific Title

Purpose

To determine whether Cardiac Magnetic Resonance Imaging (CMR) and Echocardiogram (ECHO) tests can be used to identify early signs of heart problems that can be caused by Doxil and Herceptin.

Who is this for?

Women with HER2 positive breast cancer who are going to be treated with doxorubicin (Doxil®) and trastuzumab (Herceptin®) after surgery. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will undergo the following before treatment with chemotherapy and at predetermined times during and after treatment: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MRI (Cardiac Magnetic Resonance Imaging, CMR)</li> <li class="seamTextUnorderedListItem">Ultrasound (Echocardiogram, ECHO)</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This study is investigating whether Cardiac Magnetic Resonance Imaging (CMR) and Echocardiogram (ECHO) tests can be used to identify early signs of heart problems that can be caused by Doxil and Herceptin.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02666378' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/research-news/tx-w-herceptin-needs-heart-monitoring' target='_blank'>Breastcancer.org: Women Treated With Herceptin Need Heart Monitoring</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/research-news/heart-meds-reduce-herceptin-cardiac-damage' target='_blank'>Breastcancer.org: Medicine for Herceptin Related Heart Damage</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/research-news/20111005' target='_blank'>Breastcancer.org: Herceptin Related Heart Damage</a> </li></ul>

NEAREST SITE: 2693 miles
Brigham and Women's Hospital
Boston,MA

VISITS: 1 visit every 6 months, for 2 years

PHASE: NA

NCT ID: NCT04030507

Using MRIs to Screen for Brain Metastases in Advanced Breast Cancer

Screening Magnetic Resonance Imaging of the Brain in Patients With Metastatic Breast Cancer Managed With First/Second Line Chemotherapy or Inflammatory Breast Cancer Managed With Definitive Intent: A Prospective Study Scientific Title

Purpose

To study if using MRIs to screen for brain metastases (breast cancer that has spread to the brain) is safe and finds brain metastases earlier than the standard of care (no screening).

Who is this for?

People with advanced (some stage III) or metastatic (stage IV) breast cancer who will be starting their first or second chemotherapy for advanced disease. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be assigned to 1 of 3 groups depending upon your cancer subtype: Group 1: Triple negative <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Brain MRI, every 6 months for 2 years</li> </ul> Group 2: Inflammatory <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Brain MRI, every 6 months for 2 years</li> </ul> Group 3: Hormone positive or HER2 positive People in Group 3 will be randomly assigned to receiving screening or no screening Screening group <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Brain MRI, every 6 months for 2 years</li> </ul> No screening group <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">No brain MRIs</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Brain metastases (brain mets) is when breast cancer has spread to the brain. </li> <li class="seamTextUnorderedListItem">The standard of care for metastatic breast cancer does not include ongoing screening for brain metastases.</li> <li class="seamTextUnorderedListItem">This imaging trial will use regularly scheduled MRIs (magnetic resonance imaging) to look for brain mets.</li> <li class="seamTextUnorderedListItem">Researchers believe adding brain metastases screening to the standard of care will help doctors find brain mets earlier--when they are smaller and potentially easier to manage.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04030507' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayoclinic.org/tests-procedures/mri/about/pac-20384768' target='_blank'>Mayo Clinic: Brain MRI</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.radiologybusiness.com/topics/policy/brain-mri-could-id-metastases-breast-cancer-patients-guidelines-dont-recommend-it' target='_blank'>Radiology Business: Brain MRI Could ID Metastases in Breast Cancer Patients</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancertodaymag.org/Pages/Spring2019/Looking-for-Brain-Metastases.aspx' target='_blank'>Cancer Today: Looking for Brain Metastases</a> </li></ul>

NEAREST SITE: 2694 miles
Boston Medical Center
Boston,MA

VISITS: Up to 7 visits

PHASE: NA

NCT ID: NCT02510456

Evaluating an Imaging Tool to Monitor Tumor Response to Chemo Given Before Surgery

Monitoring Neoadjuvant Chemotherapy Response In Breast Cancer Patients Using Diffuse Optical Spectroscopic Imaging (DOSI) Scientific Title

Purpose

To investigate whether DOSI is an effective way to evaluate how a tumor is responding to chemotherapy given before surgery.

Who is this for?

Women with advanced (some stage III) or metastatic (stage IV) breast cancer who are planning to receive neoadjuvant chemotherapy before surgery. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Up to 7 imaging scans at 7 different time points during the course of chemotherapy treatment</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Giving chemotherapy before surgery, called neoadjuvant treatment, allows researchers to study how the tumor is responding to the treatment.</li> <li class="seamTextUnorderedListItem">Diffuse Optical Spectroscopy Imaging (DOSI) uses a handheld device that is placed against the skin to assess tumor metabolic activity.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02510456' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://clinicaltrials.gov/ct2/show/NCT02510456?term=NCT02510456&rank=1' target='_blank'>ClinicalTrials.gov: Trial Information</a> </li><li class='seamTextUnorderedListItem'><a href='https://sites.google.com/site/dosiatbli/' target='_blank'>Information about DOSI</a> </li></ul>

Browse Trials

Narrow my choices:

Breast Cancer Screening Based on Individual Risk Factors and Comparing the Effectiveness of 3D to 2D Mammography

Contact Research Sites

WISDOM Study: Women Informed to Screen Depending on Measures of Risk

Contact Research Sites

Detection of Cancer Cells During Lumpectomy in Women Who Received Therapy Before Surgery

Contact Research Sites

Imaging and Tumor Mark Tests to Monitor Metastatic HR Positive, HER2 Negative Breast Cancer

Contact Research Sites

Using PET/CT Scans to See How Breast Cancer That Has Spread to the Bones is Responding to Therapy

Contact Research Sites

Studying the Effects of Anti-Estrogen Therapy on the Brain of Women with Stage I-III Breast Cancer

Contact Research Sites

Predicting Which Tumors in People With Newly Diagnosed Metastatic ER+ Breast Cancer Will Respond to Hormone Therapy

Contact Research Sites

Two Chemotherapies and a Targeted Therapy Before Surgery for Stage I-III Breast Cancer

Contact Research Sites

Using a PET/CT Scan to Find Lobular Breast Cancer Cells Before Surgery for Stage I-IV Lobular Breast Cancer

Contact Research Sites

Using Brain Imaging to Study the Effect of Chemotherapy on the Brain

Contact Research Sites

Metabolic Differences Between Brain Metastases and Normal Brain Tissue

Contact Research Sites

DECT Imaging Before Stereotactic Radiosurgery to Detect Brain Metastases

Contact Research Sites

Advanced MRI Scan Before and After Radiation Therapy to Detect Brain Metastases

Contact Research Sites

An Experimental PET/CT Scan to Find PARP-Expressing Tumor Cells

Contact Research Sites

Imaging to Personalize Amount of Tamoxifen in Advanced, ER+, HER2- Breast Cancer With a ESR1 Mutation

Contact Research Sites

A Circulating Tumor Cell Test To Screen For Breast Cancer At Walter Reed National Military Medical Center

Contact Research Sites

A New Approach to Studying How ER+ Tumors Respond to Treatment

Contact Research Sites

Additional Therapy after Standard Treatment for Women with Stage I-III, ER+, HER2- Breast Cancer with Residual Disease by ctDNA Testing

Contact Research Sites

Detecting Treatment-Related Cardiotoxicity in HER2 Positive Breast Cancer

Contact Research Sites

Using MRIs to Screen for Brain Metastases in Advanced Breast Cancer

Contact Research Sites

Evaluating an Imaging Tool to Monitor Tumor Response to Chemo Given Before Surgery

Contact Research Sites

Connect

Site Map